Acute cholestatic hepatitis probably associated with risperidone.

Area of Science:

• Pharmacology
• Hepatology
• Clinical Toxicology

Background:

• Risperidone, an atypical antipsychotic, is generally considered to have a favorable hepatic safety profile compared to older neuroleptics.
• However, idiosyncratic hepatotoxicity associated with risperidone has been reported, necessitating careful patient monitoring.
• The potential for drug interactions to exacerbate liver injury risk requires further investigation.

Observation:

• A case study involving a 64-year-old male patient treated concurrently with risperidone and fluoxetine is presented.
• The patient experienced acute cholestatic hepatitis after initiating risperidone therapy, evidenced by a rapid elevation in liver enzymes within days of starting the medication.
• This adverse event occurred despite the patient receiving a low dose of risperidone (2 mg/day) for a short duration.

Findings:

• The clinical presentation strongly suggests a probable association between risperidone use, in conjunction with fluoxetine, and the development of acute cholestatic hepatitis.
• The rapid onset of liver injury indicates a potential synergistic or additive toxic effect between these two pharmacologically active agents.
• This case highlights a specific instance of drug-induced liver injury (DILI) that warrants attention in clinical practice.

Implications:

• Baseline liver function tests are recommended prior to initiating risperidone therapy, particularly in patients also prescribed fluoxetine.
• Regular monitoring of liver function tests during concurrent therapy with risperidone and fluoxetine is crucial for early detection of potential hepatotoxicity.
• This case underscores the importance of considering drug interactions when assessing the risk of adverse hepatic events in patients undergoing psychotropic medication regimens.